- Home
- SGML vs MGTX Comparison
SGML vs MGTX Comparison
Compare SGML & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- MGTX
- Stock Information
- Founded
- SGML 2011
- MGTX 2015
- Country
- SGML Brazil
- MGTX United States
- Employees
- SGML N/A
- MGTX N/A
- Industry
- SGML Industrial Machinery/Components
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGML Industrials
- MGTX Health Care
- Exchange
- SGML Nasdaq
- MGTX Nasdaq
- Market Cap
- SGML 743.4M
- MGTX 670.2M
- IPO Year
- SGML N/A
- MGTX N/A
- Fundamental
- Price
- SGML $7.49
- MGTX $8.45
- Analyst Decision
- SGML Strong Buy
- MGTX Strong Buy
- Analyst Count
- SGML 1
- MGTX 2
- Target Price
- SGML $16.00
- MGTX $24.00
- AVG Volume (30 Days)
- SGML 2.6M
- MGTX 337.6K
- Earning Date
- SGML 11-14-2025
- MGTX 11-12-2025
- Dividend Yield
- SGML N/A
- MGTX N/A
- EPS Growth
- SGML N/A
- MGTX N/A
- EPS
- SGML N/A
- MGTX N/A
- Revenue
- SGML $134,494,014.00
- MGTX $37,917,000.00
- Revenue This Year
- SGML $40.75
- MGTX $144.79
- Revenue Next Year
- SGML $39.56
- MGTX $168.58
- P/E Ratio
- SGML N/A
- MGTX N/A
- Revenue Growth
- SGML N/A
- MGTX 366.84
- 52 Week Low
- SGML $4.25
- MGTX $3.97
- 52 Week High
- SGML $15.56
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- SGML 64.57
- MGTX 63.13
- Support Level
- SGML $6.33
- MGTX $8.15
- Resistance Level
- SGML $7.35
- MGTX $8.49
- Average True Range (ATR)
- SGML 0.48
- MGTX 0.40
- MACD
- SGML 0.11
- MGTX 0.07
- Stochastic Oscillator
- SGML 89.69
- MGTX 81.18
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.